Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

36.55 -0.90 (-2.39%)
Streaming Delayed Price Updated: 10:44 AM EDT, Mar 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
News headline image
Novo Nordisk A/S Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NVO
From DJS Law Group
Via Business Wire
News headline image
Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs ↗
To gain an edge, this is what you need to know today. 
Via Benzinga
News headline image
NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th
From Bragar Eagel & Squire
Via GlobeNewswire
Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know. ↗
Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story. 
Via The Motley Fool
News headline image
3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now ↗
These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples. 
Via The Motley Fool
Topics World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗
Via Stocktwits
Topics Government
News headline image
Faruqi & Faruqi Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Does This Acquisition Make Pfizer Stock a Great Buy? ↗
There's an opportunity to get in on the weight-loss drug craze at a reasonable price. 
Via The Motley Fool
Topics Death Intellectual Property
News headline image
DEADLINE NEXT WEEK: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Contact the Firm Before September 30, 2025
From Berger Montague
Via GlobeNewswire
News headline image
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today ↗
The latest data from the company's oral weight loss drug is bullish for the stock. 
Via The Motley Fool
Topics Economy
News headline image
3 Reasons to Buy Novo Nordisk Stock Right Now ↗
The pharmaceutical leader is gradually laying the groundwork for a strong rebound. 
Via The Motley Fool
News headline image
NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm Before September 30th
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset ↗
 
Via Benzinga
Topics ETFs
News headline image
NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug ↗
Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug. 
Via Investor's Business Daily
News headline image
Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape
As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Roche Targets Top Spot In Weight Loss Drug Market ↗
Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions. 
Via Benzinga
News headline image
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron
Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity... 
Via MarketMinute
Topics Economy
News headline image
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Levi &amp; Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
3 Dirt-Cheap Stocks to Buy Right Now ↗
These stocks share several common denominators, including attractive valuations. 
Via The Motley Fool
Topics Intellectual Property
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
From Bernstein Liebhard LLP
Via GlobeNewswire
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.